Beginning Nov. 20, 2023, every U.S. household can again place an order to receive four more free COVID-19 rapid tests delivered to their home by visiting COVIDTests.gov. If you did not order tests this fall, you may place two orders for a total of eight tests. Additionally, before you discard any “expired” test kits you have, please check here to see if the expiration dates of your COVID-19 tests have been extended.

| CTR Home | Data & Statistics | Research | Resources for Registrars | Reporting RequirementsOther Resources | Contact CTR

 

 

Health care providers, clinical laboratories, and hospitals are required by Connecticut statute (Chapter 368a, Section 19a-72) to report all cases of malignant tumors (and associated conditions) to CTR.  Timelines for reporting and civil penalties associated with failure to report are described in the statute.  Facility reporting to CTR does not violate HIPAA regulations.

 

 

FAQs

 

Q:  What are the changes to reportability applicable to cases diagnosed in 2018 and forward? 
A:  The following links provide specific information on 2018 updates to reporting requirements: 

            Updated 2018 Guidelines (.pdf)
           
Updated 2018 ICD-O-3 Numeric Table (.pdf)
           
Updated 2018 ICD-O-3 Table (.xlsx)
           
ICD-O-3 Table Errata (.pdf)
 

 

Q:  Which cancer cases and data must be reported? 
A:  The following links detail specific cancer reporting requirements: 

            2022 Reportable List

            FY 2021 ICD-10 Casefinding List

            2020-2021 Required Data Fields Table-NAACCR Item Order  

 

Q: What options are available for submitting reports to CTR? 
A: Facilities can report either electronically or via hard copy.
Contact CTR for more information.

 

Reporting Forms

           Patient Reporting Form Form-Sept 2022

 

 

Have further questions about reporting?  Please contact CTR's Registrar of Tumor Records.

 

 

Useful reporting links:

   

 
 
 
 
 
 
 
 
 
 
 
 
 
 
  

For more information, please contact CTR at (860) 509-7163.

 

 

This work has been supported by federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800002I.